311 related articles for article (PubMed ID: 35122171)
21. Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B.
Jia YX; Cui FQ; Li L; Zhang DL; Zhang GM; Wang FZ; Gong XH; Zheng H; Wu ZH; Miao N; Sun XJ; Zhang L; Lv JJ; Yang F
Qual Life Res; 2014 Oct; 23(8):2355-63. PubMed ID: 24627090
[TBL] [Abstract][Full Text] [Related]
22. Psychometric validation of the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) in Chinese patients with adolescent idiopathic scoliosis.
Cheung PWH; Wong CKH; Samartzis D; Luk KDK; Lam CLK; Cheung KMC; Cheung JPY
Scoliosis Spinal Disord; 2016; 11():19. PubMed ID: 27525314
[TBL] [Abstract][Full Text] [Related]
23. Psychometric properties comparison between EQ-5D-5L and EQ-5D-3L in the general Thai population.
Kangwanrattanakul K; Parmontree P
Qual Life Res; 2020 Dec; 29(12):3407-3417. PubMed ID: 32780315
[TBL] [Abstract][Full Text] [Related]
24. Assessing validity of the EQ-5D-5L proxy in children and adolescents with Duchenne muscular dystrophy or spinal muscular atrophy.
Xu RH; Dai Y; Ng SSM; Tsang HWH; Zhang S; Dong D
Eur J Health Econ; 2024 Feb; 25(1):103-115. PubMed ID: 36809586
[TBL] [Abstract][Full Text] [Related]
25. Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases.
Scalone L; Ciampichini R; Fagiuoli S; Gardini I; Fusco F; Gaeta L; Del Prete A; Cesana G; Mantovani LG
Qual Life Res; 2013 Sep; 22(7):1707-16. PubMed ID: 23192232
[TBL] [Abstract][Full Text] [Related]
26. Comparing measurement properties of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients.
Fitriana TS; Purba FD; Rahmatika R; Muhaimin R; Sari NM; Bonsel G; Stolk E; Busschbach JJV
Health Qual Life Outcomes; 2021 Nov; 19(1):256. PubMed ID: 34781978
[TBL] [Abstract][Full Text] [Related]
27. A head-to-head comparison of the measurement properties of EQ-5D-3L and EQ-5D-5L in Chinese family caregivers of cancer patients.
Zhang H; Liu B; Gu W; Cao Y; Xu J; Tan RL; Chang E; Zheng W; Li H; Zhou L; Jia Y; Yang H; Guo S; Huang W; Luo N
Support Care Cancer; 2023 Dec; 32(1):14. PubMed ID: 38060009
[TBL] [Abstract][Full Text] [Related]
28. The EQ-5D-5L Is Superior to the -3L Version in Measuring Health-related Quality of Life in Patients Awaiting THA or TKA.
Jin X; Al Sayah F; Ohinmaa A; Marshall DA; Smith C; Johnson JA
Clin Orthop Relat Res; 2019 Jul; 477(7):1632-1644. PubMed ID: 30801280
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis.
Yfantopoulos J; Chantzaras A; Kontodimas S
Arch Dermatol Res; 2017 Jul; 309(5):357-370. PubMed ID: 28528371
[TBL] [Abstract][Full Text] [Related]
30. Reliability and validity of the EQ-5D-5L compared to the EQ-5D-3L in patients with osteoarthritis referred for hip and knee replacement.
Conner-Spady BL; Marshall DA; Bohm E; Dunbar MJ; Loucks L; Al Khudairy A; Noseworthy TW
Qual Life Res; 2015 Jul; 24(7):1775-84. PubMed ID: 25555837
[TBL] [Abstract][Full Text] [Related]
31. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients.
Pickard AS; De Leon MC; Kohlmann T; Cella D; Rosenbloom S
Med Care; 2007 Mar; 45(3):259-63. PubMed ID: 17304084
[TBL] [Abstract][Full Text] [Related]
32. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis.
Koszorú K; Hajdu K; Brodszky V; Bató A; Gergely LH; Kovács A; Beretzky Z; Sárdy M; Szegedi A; Rencz F
Eur J Health Econ; 2023 Feb; 24(1):139-152. PubMed ID: 35412162
[TBL] [Abstract][Full Text] [Related]
33. An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L.
Khanna D; Khadka J; Mpundu-Kaambwa C; Chen G; Dalziel K; Devlin N; Ratcliffe J;
Pharmacoeconomics; 2024 Jun; 42(Suppl 1):113-128. PubMed ID: 38280125
[TBL] [Abstract][Full Text] [Related]
34. Validity of the EQ-5D-5L questionnaire among the general population of Poland.
Młyńczak K; Golicki D
Qual Life Res; 2021 Mar; 30(3):817-829. PubMed ID: 33099710
[TBL] [Abstract][Full Text] [Related]
35. A head-to-head comparison of measurement properties of the EQ-5D-3L and EQ-5D-5L in acute myeloid leukemia patients.
Yu H; Zeng X; Sui M; Liu R; Tan RL; Yang J; Huang W; Luo N
Qual Life Res; 2021 Mar; 30(3):855-866. PubMed ID: 32965633
[TBL] [Abstract][Full Text] [Related]
36. Psychometric Properties of EQ-5D-3L and EQ-5D-5L in Cognitively Impaired Patients Living with Dementia.
Michalowsky B; Hoffmann W; Xie F
J Alzheimers Dis; 2021; 83(1):77-87. PubMed ID: 34275901
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the EQ-5D-Y-5L, EQ-5D-Y-3L and PedsQL in children and adolescents.
Verstraete J; Scott D
J Patient Rep Outcomes; 2022 Jun; 6(1):67. PubMed ID: 35708825
[TBL] [Abstract][Full Text] [Related]
38. Validity of EQ-5D-5L in stroke.
Golicki D; Niewada M; Buczek J; Karlińska A; Kobayashi A; Janssen MF; Pickard AS
Qual Life Res; 2015 Apr; 24(4):845-50. PubMed ID: 25347978
[TBL] [Abstract][Full Text] [Related]
39. Validity and responsiveness of EQ-5D-Y in children with haematological malignancies and their caregivers.
Zhou W; Shen A; Yang Z; Wang P; Wu B; Herdman M; Busschbach J; Luo N
Eur J Health Econ; 2024 Feb; ():. PubMed ID: 38356007
[TBL] [Abstract][Full Text] [Related]
40. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.
Poór AK; Rencz F; Brodszky V; Gulácsi L; Beretzky Z; Hidvégi B; Holló P; Kárpáti S; Péntek M
Qual Life Res; 2017 Dec; 26(12):3409-3419. PubMed ID: 28875430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
